Badanie testuje nowy lek (Trilaciclib) podawany razem z immunoterapią i chemioterapią. Trilaciclib ma chronić zdrowe komórki krwi przed szkodą chemioterapii. Uczestniczy 50 pacjentów z nowo rozpoznanym rakiem piersi potrójnie ujemnym. Leczenie podawane przed operacją.
Trilaciclib
1 clinical trials involving this therapy/drug
This is not medical advice - consult your oncologist
Descriptions are automatically translated with AI assistance. Always verify details in the original on ClinicalTrials.gov and consult your treating physician.
NCT06955156ClinicalTrials.gov ↗
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.